Janux Taps YESCARTA® Vet as New CMO Amidst High-Stakes Pipeline Push

SAN DIEGO, CA – January 26, 2026 – Janux Therapeutics has appointed Dr. William Go, a seasoned oncology expert with a pivotal role in the approval of the groundbreaking CAR T-cell therapy YESCARTA®, as its new Chief Medical Officer. The move, effective today, comes at a critical juncture for the clinical-stage biopharmaceutical company as it aims to navigate its promising yet challenging pipeline of tumor-activated immunotherapies through late-stage development while grappling with intense investor scrutiny.

Dr. Go succeeds Dr. Zachariah McIver, who is leaving the company to pursue other opportunities. The appointment is widely seen as a strategic maneuver to bolster Janux’s clinical and regulatory capabilities with a leader whose resume includes one of modern oncology’s most significant success stories. This infusion of proven leadership is aimed squarely at guiding Janux’s proprietary platforms toward the market, a journey that has recently been marked by both scientific promise and significant market volatility.

“Janux is entering an important new phase as our programs advance and the complexity of our clinical and regulatory efforts increases,” said David Campbell, Ph.D., President and Chief Executive Officer of Janux Therapeutics, in a statement. “Will brings a combination of early- and late-stage development experience, regulatory leadership, and launch execution that will strengthen our organization as we scale.”

A Strategic Hire with a Landmark Track Record

Dr. Go’s appointment is significant not just for his two decades of experience in hematology and oncology, but for the specific nature of his achievements. His most notable accomplishment was at Kite Pharma, where he led the pivotal ZUMA-1 trial for YESCARTA®. That trial was instrumental in securing both FDA and EMA approval for the therapy, marking the first time a CAR T-cell therapy was approved for large B-cell lymphoma and heralding a new era in cancer treatment.

His expertise in navigating the complex path from a novel therapeutic concept to a globally approved drug is precisely what a company like Janux needs as it matures. After Kite was acquired by Gilead Sciences, Dr. Go continued in a senior clinical development role, further cementing his expertise in the cell therapy space. His career also includes a recent tenure as Chief Medical Officer at A2 Biotherapeutics, where he oversaw the launch of three Phase 1 trials for logic-gated CAR T-cell therapies aimed at solid tumors—a notoriously difficult area for cell therapies to penetrate.

Earlier in his career at Amgen, Dr. Go contributed to the global label expansion of Vectibix®, a key therapy for colorectal cancer. This diverse background, spanning from biomarker strategy to pivotal trial execution and blockbuster launches, provides Janux with a leader equipped for the multifaceted challenges of late-stage drug development.

Navigating a High-Stakes Clinical Gauntlet

The timing of Dr. Go’s arrival is crucial. Janux is built on its proprietary TRACTr (Tumor Activated T Cell Engager), TRACIr (Tumor Activated Immunomodulator), and ARM (Adaptive Immune Response Modulator) platforms. These technologies are designed to solve a critical problem in immunotherapy: activating the immune system to attack cancer cells only within the tumor microenvironment, thereby sparing healthy tissue and reducing the severe side effects that can plague other powerful treatments.

Two lead candidates are currently in Phase 1 trials. JANX007 targets prostate-specific membrane antigen (PSMA) for patients with metastatic castration-resistant prostate cancer (mCRPC). JANX008 targets the epidermal growth factor receptor (EGFR) and is being studied across a wide range of solid tumors. While the company has reported encouraging safety and efficacy signals, the path has not been smooth.

Recent interim data updates have triggered significant market reactions. Following one such update late last year, the company’s stock plunged over 40% in post-market trading amid investor concerns. Reports pointed to a “notable deterioration” in key efficacy metrics like PSA reduction and overall response rates compared to earlier, smaller data sets. This volatility underscores the immense pressure on Janux to deliver consistent, compelling data as its trials mature. Dr. Go will now be at the helm of this effort, tasked with steering these programs through the clinical and regulatory gauntlet where data, not promise, is the ultimate currency.

The Competitive Frontier of Tumor-Activated Therapies

Janux operates in one of the most competitive and fast-moving fields in medicine. The concept of T-cell engagers—which act as a bridge between a patient's T-cells and tumor cells—is not new. However, Janux’s “tumor-activated” approach is its core differentiator, a built-in safety switch designed to make its therapies more precise and tolerable. Dr. Go’s deep experience with CAR T-cell therapies, which re-engineer a patient’s own cells to fight cancer, provides him with a unique perspective on the entire spectrum of immunotherapy.

His challenge will be to prove that Janux’s TRACTr platform can outperform or find a distinct niche among a sea of competitors, from established BiTEs to next-generation CAR-T and other cell therapies. The potential of the platform has already attracted high-profile validation; Janux recently entered into a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel therapeutic for solid tumors, a significant vote of confidence from a major pharmaceutical player.

In his new role, Dr. Go will be responsible for translating this scientific potential into clinical reality. “What attracts me to Janux is the strength of its science and the breadth and depth of its oncology pipeline, anchored by a differentiated, tumor-activated T-cell engager platform,” Dr. Go stated. “Janux is tackling important clinical challenges with programs designed to build on existing standards of care, and I believe the Company is well positioned to deliver meaningful advances for patients.”

With a proven leader in immunotherapy development now in a key executive position, Janux has fortified its leadership for the critical phases ahead. While analyst ratings remain largely positive, the market has made it clear that future success will be dictated by the strength and consistency of the clinical data Dr. Go will now oversee. His appointment represents a calculated and strategic investment in the expertise required to turn innovative science into an approved, life-changing medicine.